The Potential of Curcumin as Prevention and Alternative Treatment for Helicobacter Pylori Associated Diseases
DOI:
https://doi.org/10.71341/bmwj.v1i1.13Keywords:
gastritis, curcumin, gastric cancer, helicobacter pylori, peptic ulcerAbstract
Introduction: Helicobacter pylori (H. pylori) is a pathogenic bacterium found in half of the world's population, causing gastrointestinal problems ranging from gastritis and peptic ulcers to gastric cancer. Current triple therapy treatment for H. pylori faces issues of resistance, side effects, and high cost, necessitating alternative therapies. Studies suggest that curcumin, a compound found in turmeric, may have antibacterial effects against H. pylori.
Method: This literature review evaluated the potential of curcumin against H. pylori infection. Relevant articles were systematically searched in PubMed, Scopus, Web of Science, and Google Scholar databases using combinations of keywords including "curcumin," "turmeric," "Helicobacter pylori," "antibacterial," "anti-inflammatory," "antioxidant," and "bioavailability."
Results: Curcumin, a polyphenol compound extracted from turmeric, possesses antibacterial, anti-inflammatory, anti-carcinogenic, and antioxidant properties. Turmeric is a natural, inexpensive, and readily available plant in Indonesia. Curcumin prevents H. pylori-associated diseases by inhibiting bacterial adherence to gastric cells and exhibiting bactericidal effects through disruption of bacterial metabolic enzymes and inhibition of ammonia production. Additionally, curcumin treats H. pylori-induced inflammation by suppressing inflammatory pathways such as NF-κB, AP-1, JNK, and MAPK.
Conclusion: Curcumin shows potential as both a preventive and therapeutic agent for H. pylori-associated diseases. Further research should focus on improving curcumin's delivery system to enhance its efficacy in clinical applications.
References
Ak, T., & Gülçin, I. (2008). Antioxidant and radical scavenging properties of curcumin. Chemico-Biological Interactions, 174(1), 27-37.
Aljamal, A. (2011). Effects of Turmeric in Peptic Ulcer and Helicobacter pylori. Plant Sciences Research, 3(3), 25-28.
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Molecular Pharmaceutics, 4(6), 807-818.
Ayala, G., Escobedo-Hinojosa, W. I., de la Cruz-Herrera, C. F., & Romero, I. (2014). Exploring alternative treatments for Helicobacter pylori infection. World Journal of Gastroenterol, 20(6), 1450-1469.
Basniwal, R. K., Khosla, R., & Jain, N. (2014). Improving the anticancer activity of curcumin using nanocurcumin dispersion in water. Nutrition and Cancer, 66(6), 1015-1022.
Carroll, R. E., Benya, R. V., Turgeon, D. K., Vareed, S., Neuman, M., Rodriguez, L., Kakarala, M., Carpenter, P. M., McLaren, C., Meyskens, F. L., Jr, & Brenner, D. E. (2011). Phase IIA clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prevention Research, 4(3), 354-364.
Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., Ko, J. Y., Lin, J. T., Lin, B. R., Ming-Shiang, W., Yu, H. S., Jee, S. H., Chen, G. S., Chen, T. M., Chen, C. A., Lai, M. K., Pu, Y. S., Pan, M. H., Wang, Y. J., ... Hsieh, C. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21(4B), 2895-2900.
Cruz-Correa, M., Shoskes, D. A., Sanchez, P., Zhao, R., Hylind, L. M., Wexner, S. D., & Giardiello, F. M. (2006). Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinical Gastroenterology and Hepatology, 4(8), 1035-1038.
Dadhaniya, P., Patel, C., Muchhara, J., Bhadja, N., Mathuria, N., Vachhani, K., & Soni, M. G. (2011). Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies. Food and Chemical Toxicology, 49(8), 1834-1842.
De, R., Kundu, P., & Swarnakar, S. (2009). Antimicrobial Activity of Curcumin against Helicobacter pylori Isolates from India and during Infections in Mice. Antimicrobial Agents and Chemotherapy, 53(4), 1592-1597.
Dikmen, M., Canturk, Z., Ozturk, Y., & Tunali, Y. (2010). Investigation of the apoptotic effect of curcumin in human leukemia HL-60 cells by using flow cytometry. Cancer Biotherapy and Radiopharmaceuticals, 25(6), 749-755.
Gossard, B., Fieldman, L., & Schmid, K. (2013). Life Extension Disease Prevention and Treatment (5th ed.). LE Publications.
Gupta, S. C., Prasad, S., Kim, J. H., Patchva, S., Webb, L. J., Priyadarsini, I. K., & Aggarwal, B. B. (2011). Multitargeting by curcumin as revealed by molecular interaction studies. Natural Product Reports, 28(12), 1937-1955.
Han, C., Zhang, J., Chen, L., Chen, K., Shen, X., & Jiang, H. (2007). Discovery of Helicobacter pylori shikimate kinase inhibitors: bioassay and molecular modeling. Bioorganic & Medicinal Chemistry, 15(2), 656-662.
Hanai, H., Iida, T., Takeuchi, K., Watanabe, F., Maruyama, Y., Andoh, A., Tsujikawa, T., et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical Gastroenterology and Hepatology, 4(12), 1502-1506.
Holt, P. R., Katz, S., & Kirshoff, R. (2005). Curcumin therapy in inflammatory bowel disease: a pilot study. Digestive Diseases and Sciences, 50(11), 2191-2193.
Hsieh, Y. W., Huang, C. Y., Yang, S. Y., Peng, Y. H., Yu, C. P., Chao, P. D., & Hou, Y. C. (2014). Oral intake of curcumin markedly activated CYP 3A4: In vivo and ex vivo studies. Scientific Reports, 4, 6587.
Irving, G. R., Karmokar, A., Berry, D. P., Brown, K., & Steward, W. P. (2011). Curcumin: The potential for efficacy in gastrointestinal diseases. Best Practice & Research Clinical Gastroenterology, 25(4-5), 519-534.
Jurenka, J. S. (2009). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Alternative Medicine Review, 14, 141–153.
Khalil, N. M., do Nascimento, T. C., Casa, D. M., Dalmolin, L. F., de Mattos, A. C., Hoss, I., Romano, M. A., & Mainardes, R. M. (2013). Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids and Surfaces B: Biointerfaces, 101, 353-360.
Kidd, P. M. (2009). Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Alternative Medicine Review, 14, 226–246.
Kidd, P. M. (2009). Bioavailability and activity of phytosome complexes from botanical polyphenols: The silymarin, curcumin, green tea, and grape seed extracts. Alternative Medicine Review, 14(3), 226-246.
Koosirirat, C., Linpisarn, S., Changsom, D., Chawansuntati, K., & Wipasa, J. (2010). Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. International Immunopharmacology, 10(7), 815-820.
Kumar, D., Kumar, M., Saravanan, C., & Singh, S. K. (2012). Curcumin: a potential candidate for matrix metalloproteinase inhibitors. Expert Opinion on Therapeutic Targets, 16, 959–972.
Kumar, D., Kumar, M., Saravanan, C., & Singh, S. K. (2012). Curcumin: A potential candidate for matrix metalloproteinase inhibitors. Expert Opinion on Therapeutic Targets, 16(10), 959-972.
Kundu, P., De, R., Pal, I., Mukhopadhyay, A. K., Saha, D. R., & Swarnakar, S. (2011). Curcumin alleviates matrix metalloproteinase-3 and -9 activities during eradication of Helicobacter pylori infection in cultured cells and mice. PLoS One, 6, e16306.
Lao, C. D., Ruffin, M. T., 4th, Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., & Brenner, D. E. (2006). Dose escalation of a curcuminoid formulation. BMC Complementary and Alternative Medicine, 6, 10.
Li, C., Zhang, Y., Su, T., Feng, L., Long, Y., & Chen, Z. (2012). Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. International Journal of Nanomedicine, 7, 5995-6002.
Liu, A., Lou, H., Zhao, L., & Fan, P. (2006). Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. Journal of Pharmaceutical and Biomedical Analysis, 40(3), 720-727.
Mahady, G. B., Pendland, S. L., Yun, G., & Lu, Z. Z. (2002). Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Research, 22(6C), 4179-4181.
Maiti, K., Mukherjee, K., Gantait, A., Saha, B. P., & Mukherjee, P. K. (2007). Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. International Journal of Pharmaceutics, 330(1-2), 155-163.
Marcus, E. A., & Scott, D. R. (2016). Gastric Colonization by H. pylori. In N. Kim (Ed.), Helicobacter pylori (1st ed., pp. 23-31). Singapore: Springer.
Martin-Cordero, C., Lopez-Lazaro, M., Galvez, M., Ayuso, M. J., Toro, M. V., & Alarcon de la Lastra, C. (2003). Curcumin as a DNA topoisomerase II poison. Journal of Enzyme Inhibition and Medicinal Chemistry, 18(6), 505-509.
Morgan, D. R., & Crowe, S. E. (2016). Helicobacter pylori Infection. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease (10th ed., pp. 857-861). Philadelphia, PA: Elsevier.
Nakano, M., Hirayama, T., Moss, J., & Yahiro, K. (2016). Helicobacter pylori VacA Exhibits Pleiotropic Actions in Host Cells. In H. Suzuki, R. Warren, & B. Marshall (Eds.), Helicobacter pylori (pp. 49-66). Springer Japan.
Nasri, H., Sahinfard, N., Rafieian, M., Rafieian, S., Shirzad, M., & Rafieian-Kopaei, M. (2014). Turmeric: A spice with multifunctional medicinal properties. Journal of HerbMed Pharmacology, 3, 5–8.
Pandey, M. K., & Rangarajan, S. (2012). PEGylated Curcumin: A Potent Drug Candidate. In J. Sasaki & M. Kichida (Eds.), Curcumin: Biosynthesis, Medicinal Uses and Health Benefits (pp. 155-175). Nova Science Publishers.
Pattiyathanee, P., et al. (2009). Effect of curcumin on Helicobacter pylori biofilm formation. African Journal of Biotechnology, 8(19), 5106-511.
Prasad, S., & Aggarwal, B. B. (2011). Turmeric, the Golden Spice: From Traditional Medicine to Modern Medicine. In I. F. F. Benzie & S. Wachtel-Galor (Eds.), Herbal Medicine: Biomolecular and Clinical Aspects (2nd ed., Chapter 13). Boca Raton (FL): CRC Press/Taylor & Francis. Available from: https://www.ncbi.nlm.nih.gov/books/NBK92752/
Prasad, S., Tyagi, A. K., & Aggarwal, B. B. (2014). Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. Cancer Research and Treatment, 46(1), 2-18.
Prucksunand, C., Indrasukhsri, B., Leethochawalit, M., & Hungspreugs, K. X. (2001). Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian Journal of Tropical Medicine and Public Health, 32(1), 208-215.
Ravindran, P. N., Nirmal Babu, K., & Sivaraman, K. (2007). Turmeric. The golden spice of life. In Turmeric. The Genus Curcuma (pp. 1-14). Boca Raton, FL, USA: CRC Press.
Salih, B. A. (2009). Helicobacter pylori Infection in Developing Countries: The Burden for How Long? Saudi Journal of Gastroenterol, 15(3), 201-207.
Santos, A. M., Lopes, T., Oleastro, M., et al. (2015). Curcumin Inhibits Gastric Inflammation Induced by Helicobacter Pylori Infection in a Mouse Model. Nutrients, 7(1), 306-320.
Sarkar, A., De, R., & Mukhopadhyay, A. K. (2016). Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases. World Journal of Gastroenterol, 22(9), 2736-2748.
Sarkar, A., De, R., & Mukhopadhyay, A. K. (2016). Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases. World Journal of Gastroenterology, 22(9), 2736-2748.
Sasaki, H., Sunagawa, Y., Takahashi, K., Imaizumi, A., Fukuda, H., Hashimoto, T., Wada, H., Katanasaka, Y., Kakeya, H., Fujita, M., Hasegawa, K., & Morimoto, T. (2011). Innovative preparation of curcumin for improved oral bioavailability. Biological and Pharmaceutical Bulletin, 34(5), 660-665.
Senda, Y., & Hatakeyama, M. (2016). CagA. In H. Suzuki, R. Warren, & B. Marshall (Eds.), Helicobacter pylori (pp. 33-44). Springer Japan.
Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005). Curcumin: The story so far. European Journal of Cancer, 41(13), 1955-1968.
Sharma, V., Nehru, B., Munshi, A., & Jyothy, A. (2010). Antioxidant potential of curcumin against oxidative insult induced by pentylenetetrazol in epileptic rats. Methods and Findings in Experimental and Clinical Pharmacology, 32(4), 227-232.
Shehzad, A., Ul-Islam, M., Wahid, F., & Lee, Y. S. (2014). Multifunctional polymeric nanocurcumin for cancer therapy. Journal of Nanoscience and Nanotechnology, 14(1), 803-814.
Shmuely, H., Domniz, N., & Yahav, J. (2016). Non-pharmacological treatment of Helicobacter pylori. World Journal of Gastroenterol Pharmacol Ther, 7(2), 171-178.
Sintara, K., Thong-Ngam, D., Patumraj, S., Klaikeaw, N., & Chatsuwan, T. (2010). Curcumin suppresses gastric NF-κB activation and macromolecular leakage in Helicobacter pylori-infected rats. World Journal of Gastroenterology, 16(32), 4039-4046.
Srivastava, A. K., Kumar, V., & Roy, B. K. (2015). Insights from the molecular docking of curcumin to the virulent factors of Helicobacter pylori. Bioinformation, 11(10), 447-453.
Suresh, D., & Srinivasan, K. (2010). Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian Journal of Medical Research, 131, 682-691.
Testerman, T. L., & Morris, J. (2014). Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World Journal of Gastroenterol, 20(36), 12781-12808.
Tsai, Y. M., Chang-Liao, W. L., Chien, C. F., Lin, L. C., & Tsai, T. H. (2012). Effects of polymer molecular weight on relative oral bioavailability of curcumin. International Journal of Nanomedicine, 7, 2957-2966.
Tsai, Y. M., Jan, W. C., Chien, C. F., Lee, W. C., Lin, L. C., & Tsai, T. H. (2011). Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chemistry, 127(3), 918-925.
Weber, W. M., Hunsaker, L. A., Abcouwer, S. F., Deck, L. M., & Vander Jagt, D. L. (2005). Anti-oxidant activities of curcumin and related enones. Bioorganic & Medicinal Chemistry, 13(11), 3811-3820.
Wong, F., Rayner-Hartley, E., & Byrne, M. F. (2014). Extraintestinal manifestations of Helicobacter pylori: A concise review. World Journal of Gastroenterol, 20(34), 11950-11961.
Zhongfa, L., Chiu, M., Wang, J., Chen, W., Yen, W., Fan-Havard, P., Yee, L. D., & Chan, K. K. (2012). Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemotherapy and Pharmacology, 69(3), 679-689.
Zhou, S. F. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism, 9(4), 310-322.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Anak Agung Sagung Mirah Prabandari, Ni Nyoman Shinta Prasista Sari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
License
This work is licensed under the Creative Commons Attribution-ShareAlike 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercial purposes.
- Adaptation — mixing, changing, and developing materials for any purpose, even commercial ones.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
